
Read the latest news from Viewpoint Molecular Targeting
Click here for the details
A diagnosis is the first step towards treating your cancer.
With the many advances and options in cancer treatment, determining what is right for you can feel overwhelming.
Isoray is here to help.
We’re committed to providing a powerful, proven treatment while connecting you with the very best care teams available.

Patients & Families
Find a Doctor Near You
A diagnosis is just the first step toward treating your cancer. We are here to help you make an informedtreatment decision with your doctor so you can begin living your life again.



Years of Data
Patients Treated
Day Half Life

Treats cancer at the source

Higher energy, greater coverage

Shorter half-life for rapid resolution of side-effects

Speed of Delivery

“Cesium-131 provides everything we want for prostate brachytherapy as both a monotherapy and in combination therapy, including delivery of a high dose of radiation more quickly for high risk patients in a low dose rate ‘setting.’”

Unlock the full benefits of MRI-based treatment planning and post-implant quality assurance with Cesium-131. Now FDA-cleared for pairing with the Sirius® MRI Marker.

About Us
Isoray develops innovative, personalized brachytherapy products that effectively treat many forms of cancer.
Blog

The Merger: Paving the Way for Tomorrow
By CEO Lori Woods We began this journey with a simple truth. Standing still is never an option. And the history of Isoray underscores that reality. When Isoray was founded, we were focused on the treatment of prostate cancer utilizing Cesium-131....
Press Releases

Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders
Stockholders Approve Proposal One Clearing Way for Consummation of Merger RICHLAND, WASHINGTON – January 30, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment...
Whether you’re a Patient or a Clinician,
we’re here to help.
Call us at 1-509-375-5329